Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to $9.1 million.

  • Maravai Lifesciences Holdings' Share-based Compensation fell 30.61% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 23.68%. This contributed to the annual value of $49.4 million for FY2024, which is 42.87% up from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Share-based Compensation of $9.1 million as of Q3 2025, which was up 33.39% from $6.8 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Share-based Compensation high stood at $13.8 million for Q2 2024, and its period low was $2.2 million during Q4 2021.
  • In the last 3 years, Maravai Lifesciences Holdings' Share-based Compensation had a median value of $10.0 million in 2023 and averaged $10.0 million.
  • Over the last 5 years, Maravai Lifesciences Holdings' Share-based Compensation had its largest YoY gain of 348.43% in 2021, and its largest YoY loss of 89.72% in 2021.
  • Over the past 5 years, Maravai Lifesciences Holdings' Share-based Compensation (Quarterly) stood at $2.2 million in 2021, then skyrocketed by 168.83% to $6.0 million in 2022, then skyrocketed by 55.83% to $9.3 million in 2023, then grew by 12.88% to $10.5 million in 2024, then crashed by 30.61% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $6.8 million for Q2 2025, and $10.4 million during Q1 2025.